Currently, there are 118.79M common shares owned by the public and among those 111.93M shares have been available to trade.
Insiders at the company have transacted a total of 32 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 21 of these insider trades were purchases, accounting for 72,911 shares. Insider sales of the common stock occurred on 11 occasions, with total insider shares sold totaling 20,087 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 5.46, up 8.40%. The company’s stock has a 5-day price change of 23.02% and -1.12% over the past three months. NVAX shares are trading 10.21% year to date (YTD), with the 12-month market performance down to -41.87% lower. It has a 12-month low price of $3.53 and touched a high of $11.36 over the same period. NVAX has an average intraday trading volume of 8.20 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 30.26%, 16.64%, and -20.76% respectively.
Institutional ownership of Novavax, Inc. (NASDAQ: NVAX) shares accounts for 66.85% of the company’s 118.79M shares outstanding.
It has a market capitalization of $628.40M and a beta (3y monthly) value of 1.58. The earnings-per-share (ttm) stands at -$6.38. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.41% over the week and 7.25% over the month.
Earnings per share for the fiscal year are expected to increase by 49.86%, and 90.71% over the next financial year.
Looking at the support for the NVAX, a number of firms have released research notes about the stock. B. Riley Securities stated their Buy rating for the stock in a research note on August 09, 2023, with the firm’s price target at $15. TD Cowen coverage for the Novavax, Inc. (NVAX) stock in a research note released on April 20, 2023 offered a Market Perform rating with a price target of $10. B. Riley Securities was of a view on March 01, 2023 that the stock is Neutral, while B. Riley Securities gave the stock Buy rating on January 09, 2023, issuing a price target of $74- $37. H.C. Wainwright on their part issued Buy rating on December 30, 2022.
